These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9541081)

  • 1. Faecal occult blood screening for colorectal cancer: is it cost-effective?
    Whynes DK; Neilson AR; Walker AR; Hardcastle JD
    Health Econ; 1998 Feb; 7(1):21-9. PubMed ID: 9541081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer screening: efficiency and effectiveness.
    Gyrd-Hansen D; Søgaard J; Kronborg O
    Health Econ; 1998 Feb; 7(1):9-20. PubMed ID: 9541080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer.
    Lejeune C; Arveux P; Dancourt V; Béjean S; Bonithon-Kopp C; Faivre J
    Int J Technol Assess Health Care; 2004; 20(4):434-9. PubMed ID: 15609792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Option appraisal of population-based colorectal cancer screening programmes in England.
    Tappenden P; Chilcott J; Eggington S; Patnick J; Sakai H; Karnon J
    Gut; 2007 May; 56(5):677-84. PubMed ID: 17142648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
    Whynes DK
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
    [No Abstract]   [Full Text] [Related]  

  • 12. Filtering strategies in mass population screening for colorectal cancer: an economic evaluation.
    Walker A; Whynes DK
    Med Decis Making; 1992; 12(1):2-7. PubMed ID: 1538628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimates of costs and effects of screening for colorectal cancer in the United States.
    Byers T; Gorsky R
    Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective.
    Walker AR; Whynes DK; Hardcastle JD
    Scand J Gastroenterol; 1991 Feb; 26(2):215-8. PubMed ID: 2011707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of colorectal cancer screening in the elderly.
    Wagner JL; Herdman RC; Wadhwa S
    Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markov's modeling for screening strategies for colorectal cancer.
    Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
    Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.